Caplin Point Laboratories witnessed a sharp rise in share price on Thursday after the company has received approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai.

The approval grants access to the company to register and market its products at the large and growing Brazilian Pharmaceutical market.

Shares of the company are trading at Rs 1,535, up Rs 142, or 10.19% at the Bombay Stock Exchange (BSE) on Thursday at 1:58 p.m.

The scrip has touched an intra-day high of Rs 1,556 and low of Rs 1,399.00. The total volume of shares traded at the BSE is 35,998.